← All trials
NCT06264674
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 27, 2023
- Primary completion
- Jul 18, 2025
- Completion date
- Sep 18, 2025
- First posted
- Feb 20, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 790
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ChiesiLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.